secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276070
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer
---------------------------------------------------------------------------

- Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.
- She led commercial at Cerevel (acquired by AbbVie) and was GM Neuroscience at Lundbeck.
- Oversaw launches of REXULTI, TRINTELLIX, and ABILIFY MAINTENA (blockbuster sales).
- Will lead commercialization of lead candidate LB-102 for schizophrenia and bipolar depression.
- Company intends to grant her an inducement equity award outside its 2025 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312525276070/0001193125-25-276070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312525276070/d79831d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer